Mineralys Hails Launch-HTN Data Ahead of Lorundrostat PDUFA
Mineralys reported 46% of patients met AHA guidelines in Launch-HTN at Week 12. The positive data bolsters investor confidence ahead of a key FDA decision for its hypertension drug, lorundrostat.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed